Knowledge, attitudes and health outcomes in HIV-infected travellers to the USA.
Mahto, M;
Ponnusamy, K;
Schuhwerk, M;
Richens, J;
Lambert, N;
Wilkins, E;
Churchill, DR;
Miller, RF;
Behrens, RH;
(2006)
Knowledge, attitudes and health outcomes in HIV-infected travellers to the USA.
HIV medicine, 7 (4).
pp. 201-204.
ISSN 1464-2662
DOI: https://doi.org/10.1111/j.1468-1293.2006.00371.x
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
BACKGROUND: The USA bans entry to non-citizens unless they obtain a waiver visa. AIM: To establish how many people with HIV infection travelled to the USA, whether they were aware of the travel restriction, whether they travelled with a waiver visa and HIV inclusive medical insurance and how they managed with their antiretroviral medication (ARV). DESIGN: Collation of data from cross-sectional studies conducted independently at three different medical centres, Manchester, Brighton and London, using a structured self-completion questionnaire. RESULTS: The overall response rate was 66.6% (1113 respondents). 349 (31%) had travelled to the USA since testing HIV positive, of whom only 14.3% travelled with a waiver visa. 64% and 62% of the respondents at Manchester and Brighton were aware of the need of a waiver visa. 68.5% (212) were on ARV medication at the time of travel and, of these, 11.3% stopped their medication. Of those taking ARV medication, only 25% took a doctors' letter, 11.7% posted their medication in advance. Of those discontinuing treatment (n=27), 55.5% sought medical advice before stopping, 11 were on NNRTI-based regimen and one developed NNRTI-based mutation. Only 27% took up HIV inclusive medical insurance. Many patients reported negative practical and emotional experiences resulting from travel restrictions. CONCLUSION: The majority of HIV patients travel to the USA without the waiver visa, with nearly half doing so with insufficient planning and advice. A significant minority (11.3%) stop their medication in an unplanned manner, risking the development of drug resistance.